1. Garrett, T.P., Burgess, A.W., Gan, H.K., Luwor, R.B., Cartwright, G., Walker, F., Orchard, S.G., Clayton, A.H., Nice, E.C., Rothacker, J., Catimel, B., Cavenee, W.K., Old, L.J., Stockert, E., Ritter, G., Adams, T.E., Hoyne, P.A., Wittrup, D., Chao, G., Cochran, J.R., Luo, C., Lou, M., Huyton, T., Xu, Y., Fairlie, W.D., Yao, S., Scott, A.M., and Johns, T.G., Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A, 106(13): p. 5082-7 2009.

2. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate, 69(1): p. 92-104 2009.

3. Pillay, V., Allaf, L., Wilding, A.L., Donoghue, J.F., Court, N.W., Greenall, S.A., Scott, A.M., and Johns, T.G., The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia, 11(5): p. 448-58, 2 p following 458 2009.

4. Scott, A.M., Gunawardana, D.H., Kelley, B., Stuckey, J.G., Byrne, A.J., Ramshaw, J.E., and Fulham, M.J., PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med, 49(9): p. 1451-7 2008.

5. Li, D., Ji, H., Zaghlul, S., Mcnamara, K., Liang, M.C., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L.R., Padera, R.F., Scott, A.M., Jungbluth, A.A., Cavenee, W.K., Old, L.J., Demetri, G.D., and Wong, K.K., Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest, 117(2): p. 346-52 2007.

6. Scott, A.M., Lee, F.T., Tebbutt, N., Herbertson, R., Gill, S.S., Liu, Z., Skrinos, E., Murone, C., Saunder, T.H., Chappell, B., Papenfuss, A.T., Poon, A.M., Hopkins, W., Smyth, F.E., Macgregor, D., Cher, L.M., Jungbluth, A.A., Brechbiel, M.W., Murphy, R., Burgess, A.W., Hoffman, E.W., Johns, T.G., and Old, L.J., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A, 104(10): p. 4071-6 2007.

7. Scott, A.M., Tebbutt, N., Lee, F.T., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A.M., Hopkins, W., Smyth, F.E., Murone, C., Macgregor, D., Papenfuss, A.T., Chappell, B., Saunder, T.H., Brechbiel, M.W., Davis, I.D., Murphy, R., Chong, G., Hoffman, E.W., and Old, L.J., A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. Clin Cancer Res, 13(11): p. 3286-92 2007.

Click Here For More